Invesaro

Stocks Health care ALKS

NASDAQ · Health care

Alkermes plc. (ALKS)

Alkermes plc. brought in $1.7B of revenue over the twelve months to June 30, 2026, up 10.8% from a year earlier. Net income was $66.1M, a net margin of 4.0%. Operating cash flow minus capital spending left $480.3M of free cash flow in fiscal 2025. At June 30, 2026 it held $511.5M in cash against $1.5B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 28, 2026.

Price
$40.85
+0.15% on the day · September 25, 2026
52-week range $27.00 to $55.67
Market cap
$6.9B
Revenue (last 12 months)
$1.7B
+10.8% year on year
Net margin
4.0%
P/E
28.6
on FY2025 diluted EPS

What Alkermes plc. does

Alkermes plc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ALKS.

Revenue and profit by year

Revenue
FY18: $1.1B $1.1B FY18FY19: $1.2B $1.2B FY19FY20: $1B $1B FY20FY21: $1.2B $1.2B FY21FY22: $1.1B $1.1B FY22FY23: $1.7B $1.7B FY23FY24: $1.6B $1.6B FY24FY25: $1.5B $1.5B FY25
Net income
FY18: -$139.3M -$139.3M FY18FY19: -$196.6M -$196.6M FY19FY20: -$110.9M -$110.9M FY20FY21: -$48.2M -$48.2M FY21FY22: -$158.3M -$158.3M FY22FY23: $355.8M $355.8M FY23FY24: $367.1M $367.1M FY24FY25: $241.7M $241.7M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$1.5B$254M$241.7M$1.43$480.3M
2024$1.6B$420.6M$367.1M$2.17$405.6M
2023$1.7B$414.1M$355.8M$2.10$353.3M
2022$1.1B-$6.1M-$158.3M-$0.97-$17.2M
2021$1.2B$97.7M-$48.2M-$0.29$73.7M
2020$1B-$112.4M-$110.9M-$0.70$40.6M

Latest SEC filings

What Alkermes plc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 21, 2026
    Investor disclosure 8-K
  2. September 16, 2026
    Executive or director change 8-K
  3. August 12, 2026
    Material agreement 8-K
  4. August 3, 2026
    Executive or director change 8-K/A
  5. July 28, 2026
    Employee stock plan registration S-8
  6. July 28, 2026
    Quarterly report 10-Q · period to June 30, 2026
  7. July 28, 2026
    Quarterly results 8-K
  8. July 8, 2026
    Material agreement ended 8-K
  9. June 15, 2026
    Investor disclosure 8-K
  10. May 20, 2026
    Executive or director change 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 18, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about ALKS

What does Alkermes plc. do?

Alkermes plc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ALKS.

Is Alkermes plc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $66.1M on revenue of $1.7B, a net margin of 4.0%.

How much revenue does Alkermes plc. make?

Over the twelve months to June 30, 2026 Alkermes plc. reported revenue of $1.7B. That is 10.8% more than a year earlier.

When did Alkermes plc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 28, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 21, 2026.

Similar companies

JNJ
Johnson & Johnson
LLY
ELI LILLY & Co
MRK
Merck & Co., Inc.
PFE
Pfizer Inc
ABBV
AbbVie Inc.
AZN
Astrazeneca PLC

Follow ALKS

Get an email when Alkermes plc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ALKS: get an email when it files

Where the numbers come from

Financial figures are the values Alkermes plc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.